OTHER INFORMATION
−Removed: During the quarter ended March 31, 2026, none of our
−Removed: directors or officers adopted, modified or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements as
−Removed: defined in Item 408 of Regulation S-K.
+Added: the three and six months ended June 30, 2026, none of our directors or officers adopted , modified or terminated any Rule 10b5-1 trading
+Added: arrangements or non-Rule 10b5-1 trading arrangements as defined in Item 408 of Regulation S-K.
+Added: Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on April 13, 2026
+Added: Certificate of Amendment to the Certificate of Incorporation of Aspire Biopharma Holdings, Inc., filed with the Secretary of State of the State of Delaware on May 11, 2026.
Form of Purchase Agreement (incorporated by reference from Exhibit 10.1 to the Current Report 8-K filed with the SEC on February 20, 2025)
1 unchanged sentence
Form of Securities Purchase Agreement (incorporated by reference from Exhibit 10.1 to the Current Report 8-K filed with the SEC on February 21, 2025)
−Removed: Form of Debenture (incorporated by reference from Exhibit 10.40 to the Current Report 8-K filed with the SEC on February 21, 2025)
+Added: Form of Debenture
Purchase Agreement, dated November 11, 2025, between Aspire Biopharma Holdings, Inc.
1 unchanged sentence
(incorporated by reference from Exhibit 10.1 to the Current Report on Form 8-K filed November 14, 2025)
+Added: Form of Purchase Agreement, dated June 10, 2026, by and among Aspire Biopharma Holdings, Inc.
+Added: and FireFish TopCo, LLC
+Added: Escrow and Closing Agreement, dated as of August 6, 2026, by and between FireFish TopCo, LLC and Aspire Biopharma Holdings, Inc.
+Added: (incorporated by reference from Exhibit 10.2 to the Current Report on Form 8-K filed August 10, 2026).
+Added: Convertible Promissory Note Purchase Agreement, dated as of August 6, 2026, by and among Aspire Biopharma Holdings, Inc.
+Added: and the Investors named therein (incorporated by reference from Exhibit 10.3 to the Current Report on Form 8-K filed August 10, 2026).
+Added: Form of Convertible Promissory Note ( incorporated by reference from Exhibit 10.4 to the Current Report on Form 8-K filed August 10, 2026).
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12 unchanged sentences
Filed herewith.
+Added: BIOPHARMA HOLDINGS, INC.
+Added: 10-Q FOR THE QUARTER ENDED JUNE 30, 2026
accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
−Removed: ASPIRE BIOPHARMA HOLDINGS, INC.
−Removed: Chief Executive Officer and Chairman
−Removed: (Principal Executive Officer)
−Removed: Chief Financial Officer
−Removed: (Principal Financial and Accounting Officer)
+Added: BIOPHARMA HOLDINGS, INC.
+Added: August 13, 2026
+Added: Executive Officer and Chairman
+Added: Executive Officer)
+Added: August 13, 2026
+Added: Financial Officer
+Added: Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.